Logo image of GLTO

GALECTO INC (GLTO) Stock Price, Quote, News and Overview

NASDAQ:GLTO - Nasdaq - US36322Q2066 - Common Stock - Currency: USD

2.42  -0.01 (-0.41%)

After market: 2.36 -0.06 (-2.48%)

GLTO Quote, Performance and Key Statistics

GALECTO INC

NASDAQ:GLTO (4/21/2025, 8:18:03 PM)

After market: 2.36 -0.06 (-2.48%)

2.42

-0.01 (-0.41%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High18.5
52 Week Low2.01
Market Cap3.19M
Shares1.32M
Float1.27M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)04-28 2025-04-28
IPO10-29 2020-10-29


GLTO short term performance overview.The bars show the price performance of GLTO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

GLTO long term performance overview.The bars show the price performance of GLTO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of GLTO is 2.42 USD. In the past month the price decreased by -60.33%. In the past year, price decreased by -86.27%.

GALECTO INC / GLTO Daily stock chart

GLTO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 16.81 301.01B
AMGN AMGEN INC 13.81 147.14B
GILD GILEAD SCIENCES INC 22.63 130.06B
VRTX VERTEX PHARMACEUTICALS INC 1646.62 122.76B
REGN REGENERON PHARMACEUTICALS 12.3 61.38B
ARGX ARGENX SE - ADR 320.27 36.37B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.28B
ONC BEIGENE LTD-ADR N/A 24.70B
BNTX BIONTECH SE-ADR N/A 24.47B
NTRA NATERA INC N/A 19.23B
SMMT SUMMIT THERAPEUTICS INC N/A 18.60B
BIIB BIOGEN INC 7.07 17.05B

About GLTO

Company Profile

GLTO logo image Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Boston, Massachusetts and currently employs 13 full-time employees. The company went IPO on 2020-10-29. The firm is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.

Company Info

GALECTO INC

75 State Street, Suite 100

Boston MASSACHUSETTS DK-2200 US

CEO: Hans T. Schambye

Employees: 13

Company Website: https://galecto.com/

Investor Relations: https://ir.galecto.com/

Phone: 14570705210

GALECTO INC / GLTO FAQ

What is the stock price of GALECTO INC today?

The current stock price of GLTO is 2.42 USD. The price decreased by -0.41% in the last trading session.


What is the ticker symbol for GALECTO INC stock?

The exchange symbol of GALECTO INC is GLTO and it is listed on the Nasdaq exchange.


On which exchange is GLTO stock listed?

GLTO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GALECTO INC stock?

8 analysts have analysed GLTO and the average price target is 8.16 USD. This implies a price increase of 237.19% is expected in the next year compared to the current price of 2.42. Check the GALECTO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GALECTO INC worth?

GALECTO INC (GLTO) has a market capitalization of 3.19M USD. This makes GLTO a Nano Cap stock.


How many employees does GALECTO INC have?

GALECTO INC (GLTO) currently has 13 employees.


What are the support and resistance levels for GALECTO INC (GLTO) stock?

GALECTO INC (GLTO) has a resistance level at 2.58. Check the full technical report for a detailed analysis of GLTO support and resistance levels.


Should I buy GALECTO INC (GLTO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GALECTO INC (GLTO) stock pay dividends?

GLTO does not pay a dividend.


When does GALECTO INC (GLTO) report earnings?

GALECTO INC (GLTO) will report earnings on 2025-04-28.


What is the Price/Earnings (PE) ratio of GALECTO INC (GLTO)?

GALECTO INC (GLTO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-17.62).


What is the Short Interest ratio of GALECTO INC (GLTO) stock?

The outstanding short interest for GALECTO INC (GLTO) is 1.44% of its float. Check the ownership tab for more information on the GLTO short interest.


GLTO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

GLTO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to GLTO. GLTO has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GLTO Financial Highlights

Over the last trailing twelve months GLTO reported a non-GAAP Earnings per Share(EPS) of -17.62. The EPS increased by 51.73% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -125.14%
ROE -135.42%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%12.83%
Sales Q2Q%N/A
EPS 1Y (TTM)51.73%
Revenue 1Y (TTM)N/A

GLTO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to GLTO. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners13.05%
Ins Owners3.61%
Short Float %1.44%
Short Ratio1.01
Analysts
Analysts82.5
Price Target8.16 (237.19%)
EPS Next Y16.06%
Revenue Next YearN/A